Crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector ZENEO®. ZENEO® is no less than 12 years of R&D and more than 400 obtained patents. Currently, 8 treatments are in advanced stages of development, which 7 for emergency situations. With its unique know-how, Crossject aims to become a world leader in the self-administration of emergency needle free injectables. Listed on the Alternext (Euronext Paris) market since February 2014, the company has completed three fund raising campaigns and furthermore received financing from the French Ministry of Defense and grants from Bpifrance as part of the Investissements d'Avenir program.